[Screening of adult Ph-like acute lymphoblastic leukemia by multiplex real-time quantitative PCR]

[Diagnosis of adult Philadelphia chromosome-like acute lymphoblastic leukemia by fluorescence in situ hybridization]

目的

建立应用荧光原位杂交技术（FISH）筛查成人Ph样急性淋巴细胞白血病（ALL）的体系。

方法

根据Ph样ALL的遗传学特征，设计了针对ABL1、ABL2、JAK2、EPOR、CRLF2、CSF1R、PDGFRB、P2RY8等基因断裂重排的FISH探针；对BCR-ABL1、ETV6-RUNX1、MLL基因断裂重排和E2A断裂重排均阴性的B-ALL，采用FISH进行Ph样ALL筛查，并结合流式免疫表型、靶向二代测序突变检测和RNA测序进行Ph样ALL诊断分析。

结果

2016年1月至2019年4月，南方医院血液科收治189例成人B-ALL，经FISH和（或）PCR检测，BCR-ABL1、ETV6-RUNX1、MLL断裂重排或E2A断裂重排阳性者共83例；其余106例患者接受Ph样ALL FISH探针筛查，其中，12例（11.3％）检出典型的Ph样ALL特异基因断裂重排，2例检出基因缺失。经RNA测序进一步验证，FISH检测Ph样ALL基因断裂重排结果灵敏度为71.4％，特异度为95.8％。综合免疫表型、靶向二代测序突变检测和RNA测序，共诊断融合基因阳性Ph样ALL 14例（13.2％）。

结论

FISH技术检测Ph样ALL具有较高的特异性，结合免疫表型和测序技术可完善诊断体系。

Recurrent Gastrointestinal Hemorrhage in Children with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with Dasatinib: Case Reports

Dasatinib, a second-line tyrosine kinase inhibitor (TKI), has been widely used in chronic myeloid leukemia (CML) and Philadelphia-positive B-cell acute lymphoblastic leukemia (Ph + B-ALL). Although dasatinib has been well tolerated, side effects including hemorrhage are not rare. Cases of bleeding disorders ultimately result in thrombocytopenia, but platelet aggregation dysfunction induced by dasatinib has also been demonstrated in Ph + B-ALL and CML patients. We report three Chinese children with Ph + B-ALL who received a combination treatment of chemotherapy and dasatinib and developed gastrointestinal bleeding several months later. The platelet count and clotting tests were normal, and these patients presented with dasatinib-induced platelet dysfunction. These findings reveal that physicians should be aware of and carefully monitor for side effects, including bleeding disorders.

[The expression of CRLF2 in adult Ph negative acute B lymphocytic leukemia and its prognostic significance]

目的

检测CRLF2蛋白在初诊成人非Ph阳性急性B淋巴细胞白血病（B-ALL）中的表达情况，探讨CRLF2蛋白的表达与患者临床特征、疗效及预后的关系。

方法

收集郑州大学附属肿瘤医院血液科2016年4月1日至2017年12月31日收治的103例初治成人B-ALL患者骨髓标本，应用流式细胞术CD45/SSC设门检测原始细胞CRLF2表达率，将CRLF2表达率≥20%定义为高表达组，<20%定义为低表达组，比较两组患者的临床特征及预后差异。

结果

CRLF2高表达组中位总生存（OS）、无病生存（DFS）时间分别为9.0和4.25个月，CRLF2低表达组分别为15.5和10.25个月，差异有统计学意义（P值分别为0.007、0.000）。CRLF2高表达组18个月OS率、DFS率分别为38.6%和25.1%，CRLF2低表达组分别为57.8%和42.3%，差异有统计学意义（P值分别为0.047、0.016）。多因素分析显示CRLF2高表达是影响患者OS（HR=2.991，95%CI 1.429~6.261，P=0.004）和DFS（HR=2.374，95%CI 1.146~4.960，P=0.041）的独立危险因素。

结论

合并CRLF2高表达的成人初治B-ALL患者预后不良。